Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Mometasone

Targets (2)Enzymes (1)Biointeractions (3)

Identification

Name

Mometasone

Accession Number

DB00764 (APRD00289)

Type

Small Molecule

Groups

Approved, Vet approved

Description

Mometasone is a medium-potency synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. The anti-inflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

Structure

Similar Structures

Synonyms

(+)-Mometasone
Mometason
Mometasona
Mométasone
Mometasonum

External IDs

LAS-41002 / LAS41002

International/Other Brands

Ecural (Essex pharma) / Elocom (Merck) / Elomet (Schering-Plough) / Eziwin (Intas) / mometAid (Progreś Laboratories) / Novasone (Schering-Plough)

Categories

UNII

8HR4QJ6DW8

CAS number

105102-22-5

Weight

Average: 427.361
Monoisotopic: 426.136464798

Chemical Formula

C₂₂H₂₈Cl₂O₄

InChI Key

QLIIKPVHVRXHRI-CXSFZGCWSA-N

InChI

InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

IUPAC Name

(1R,2S,10S,11S,13R,14R,15S,17S)-1-chloro-14-(2-chloroacetyl)-14,17-dihydroxy-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one

SMILES

[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Pharmacology

Indication

The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.

Associated Conditions

Pharmacodynamics

Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. The clinical significance of these findings is unknown.

Mechanism of action

Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A₂ inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone.

Target	Actions	Organism
AGlucocorticoid receptor	agonist	Human
UProgesterone receptor	agonist	Human

Absorption

Nasal spray is virtually undetectable in plasma

Volume of distribution

Not Available

Protein binding

98% to 99% (in a concentration range of 5 to 500 ng/mL).

Metabolism

Hepatic. Extensive metabolism to multiple metabolites. There are no major metabolites detectable in plasma. Upon in vitro incubation, one of the minor metabolites formed is 6ß-hydroxy-mometasone furoate. In human liver microsomes, the formation of the metabolite is regulated by cytochrome P-450 3A4.

Mometasone
6-beta-hydroxy-mometasone furoate

Route of elimination

Not Available

Half life

5.8 hours

Clearance

Not Available

Toxicity

The potential for acute toxic effects following overdose with the mometasone inhaler is low. However, habitual overuse of the product can cause symptoms of steroid overload, including menstrual irregularities, acne, obesity, and muscle weakness. Single oral doses up to 8000 µg have been studied on human volunteers with no adverse events reported.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(4R)-limonene	The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Mometasone.	Investigational
1,10-Phenanthroline	The risk or severity of adverse effects can be increased when Mometasone is combined with 1,10-Phenanthroline.	Experimental
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with Mometasone.	Approved, Investigational
Acemetacin	The risk or severity of adverse effects can be increased when Acemetacin is combined with Mometasone.	Approved, Experimental, Investigational
Acetaminophen	The risk or severity of adverse effects can be increased when Mometasone is combined with Acetaminophen.	Approved
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mometasone.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Mometasone.	Approved
Alclofenac	The risk or severity of adverse effects can be increased when Alclofenac is combined with Mometasone.	Approved, Withdrawn
Aldesleukin	Mometasone may decrease the antineoplastic activities of Aldesleukin.	Approved
Almasilate	The bioavailability of Mometasone can be decreased when combined with Almasilate.	Approved, Experimental
Alminoprofen	The risk or severity of adverse effects can be increased when Alminoprofen is combined with Mometasone.	Experimental
Aloglutamol	The bioavailability of Mometasone can be decreased when combined with Aloglutamol.	Approved
Aloxiprin	The risk or severity of adverse effects can be increased when Aloxiprin is combined with Mometasone.	Experimental
Aluminium	The bioavailability of Mometasone can be decreased when combined with Aluminium.	Approved, Investigational
Aluminium acetoacetate	The bioavailability of Mometasone can be decreased when combined with Aluminium acetoacetate.	Experimental
Aluminium glycinate	The bioavailability of Mometasone can be decreased when combined with Aluminium glycinate.	Experimental
Aluminum hydroxide	The bioavailability of Mometasone can be decreased when combined with Aluminum hydroxide.	Approved, Investigational
Ambenonium	The risk or severity of adverse effects can be increased when Mometasone is combined with Ambenonium.	Approved
Aminosalicylic Acid	The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Mometasone.	Approved
Amiodarone	The serum concentration of Mometasone can be increased when it is combined with Amiodarone.	Approved, Investigational
Amodiaquine	The serum concentration of Amodiaquine can be increased when it is combined with Mometasone.	Approved, Investigational
Amoxapine	The therapeutic efficacy of Mometasone can be decreased when used in combination with Amoxapine.	Approved
Amphotericin B	Mometasone may increase the hypokalemic activities of Amphotericin B.	Approved, Investigational
Andrographolide	The risk or severity of adverse effects can be increased when Andrographolide is combined with Mometasone.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Anisodamine is combined with Mometasone.	Investigational
Anthrax immune globulin human	The risk or severity of adverse effects can be increased when Mometasone is combined with Anthrax immune globulin human.	Approved
Antipyrine	The risk or severity of adverse effects can be increased when Antipyrine is combined with Mometasone.	Approved, Investigational
Antrafenine	The risk or severity of adverse effects can be increased when Mometasone is combined with Antrafenine.	Approved
Apalutamide	The serum concentration of Mometasone can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apocynin	The risk or severity of adverse effects can be increased when Apocynin is combined with Mometasone.	Investigational
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Mometasone.	Approved, Investigational
Aprepitant	The serum concentration of Mometasone can be increased when it is combined with Aprepitant.	Approved, Investigational
Atazanavir	The serum concentration of Mometasone can be increased when it is combined with Atazanavir.	Approved, Investigational
Atracurium besylate	Atracurium besylate may increase the adverse neuromuscular activities of Mometasone.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Mometasone.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Mometasone.	Approved
Azosemide	Mometasone may increase the hypokalemic activities of Azosemide.	Investigational
Bacillus calmette-guerin substrain connaught live antigen	The risk or severity of adverse effects can be increased when Mometasone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Bacillus calmette-guerin substrain tice live antigen	The risk or severity of adverse effects can be increased when Mometasone is combined with Bacillus calmette-guerin substrain tice live antigen.	Approved
Balsalazide	The risk or severity of adverse effects can be increased when Balsalazide is combined with Mometasone.	Approved, Investigational
Bazedoxifene	The serum concentration of Mometasone can be increased when it is combined with Bazedoxifene.	Approved, Investigational
BCG vaccine	The risk or severity of adverse effects can be increased when Mometasone is combined with BCG vaccine.	Investigational
Bendazac	The risk or severity of adverse effects can be increased when Bendazac is combined with Mometasone.	Experimental
Bendroflumethiazide	Mometasone may increase the hypokalemic activities of Bendroflumethiazide.	Approved
Benorilate	The risk or severity of adverse effects can be increased when Benorilate is combined with Mometasone.	Experimental
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mometasone.	Withdrawn
Benzoic Acid	The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Mometasone.	Approved, Investigational
Benzthiazide	Mometasone may increase the hypokalemic activities of Benzthiazide.	Approved
Benzydamine	The risk or severity of adverse effects can be increased when Benzydamine is combined with Mometasone.	Approved
Bevonium	The risk or severity of adverse effects can be increased when Bevonium is combined with Mometasone.	Experimental
Bismuth subcitrate potassium	The bioavailability of Mometasone can be decreased when combined with Bismuth Subcitrate.	Approved, Investigational
Bismuth subnitrate	The bioavailability of Mometasone can be decreased when combined with Bismuth subnitrate.	Approved
Boceprevir	The serum concentration of Mometasone can be increased when it is combined with Boceprevir.	Approved, Withdrawn
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with Mometasone.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Bucillamine is combined with Mometasone.	Investigational
Bufexamac	The risk or severity of adverse effects can be increased when Bufexamac is combined with Mometasone.	Approved, Experimental
Bumadizone	The risk or severity of adverse effects can be increased when Bumadizone is combined with Mometasone.	Experimental
Bumetanide	Mometasone may increase the hypokalemic activities of Bumetanide.	Approved
Calcitriol	The therapeutic efficacy of Calcitriol can be decreased when used in combination with Mometasone.	Approved, Nutraceutical
Calcium Carbonate	The bioavailability of Mometasone can be decreased when combined with Calcium Carbonate.	Approved, Investigational
Calcium silicate	The bioavailability of Mometasone can be decreased when combined with Calcium silicate.	Experimental
Capromab pendetide	Mometasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.	Approved
Capsaicin	The risk or severity of adverse effects can be increased when Mometasone is combined with Capsaicin.	Approved
Carbamazepine	The serum concentration of Mometasone can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbaspirin calcium	The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Mometasone.	Experimental, Investigational
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Mometasone.	Approved, Vet Approved, Withdrawn
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Mometasone.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Celecoxib is combined with Mometasone.	Approved, Investigational
Ceritinib	Mometasone may increase the hyperglycemic activities of Ceritinib.	Approved
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Mometasone.	Approved, Investigational, Vet Approved
Chlorothiazide	Mometasone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Chlorotrianisene	The serum concentration of Mometasone can be increased when it is combined with Chlorotrianisene.	Investigational, Withdrawn
Chlorphenesin	The risk or severity of adverse effects can be increased when Mometasone is combined with Chlorphenesin.	Approved, Vet Approved, Withdrawn
Chlorthalidone	Mometasone may increase the hypokalemic activities of Chlorthalidone.	Approved
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Mometasone.	Approved
Cimicoxib	The risk or severity of adverse effects can be increased when Mometasone is combined with Cimicoxib.	Investigational
Cinoxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Cinoxacin.	Approved, Investigational, Withdrawn
Ciprofloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Ciprofloxacin.	Approved, Investigational
Cisplatin	The risk or severity of adverse effects can be increased when Mometasone is combined with Cisplatin.	Approved
Clarithromycin	The serum concentration of Mometasone can be increased when it is combined with Clarithromycin.	Approved
Clodronic Acid	The risk or severity of adverse effects can be increased when Mometasone is combined with Clodronic Acid.	Approved, Investigational, Vet Approved
Clonixin	The risk or severity of adverse effects can be increased when Clonixin is combined with Mometasone.	Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)	The risk or severity of adverse effects can be increased when Mometasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).	Approved
Cobicistat	The serum concentration of Mometasone can be increased when it is combined with Cobicistat.	Approved
Colesevelam	Colesevelam can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Conjugated estrogens	The serum concentration of Mometasone can be increased when it is combined with Conjugated estrogens.	Approved
Corticorelin ovine triflutate	The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Mometasone.	Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)	The risk or severity of adverse effects can be increased when Mometasone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).	Approved
Coumaphos	The risk or severity of adverse effects can be increased when Mometasone is combined with Coumaphos.	Vet Approved
Curcumin	The risk or severity of adverse effects can be increased when Curcumin is combined with Mometasone.	Approved, Investigational
Cyclopenthiazide	Mometasone may increase the hypokalemic activities of Cyclopenthiazide.	Experimental
Daidzein	The serum concentration of Mometasone can be increased when it is combined with Daidzein.	Experimental
Danazol	Mometasone may increase the fluid retaining activities of Danazol.	Approved
Darunavir	The serum concentration of Mometasone can be increased when it is combined with Darunavir.	Approved
Decamethonium	The risk or severity of adverse effects can be increased when Mometasone is combined with Decamethonium.	Approved
Deferasirox	The risk or severity of adverse effects can be increased when Mometasone is combined with Deferasirox.	Approved, Investigational
Demecarium	The risk or severity of adverse effects can be increased when Mometasone is combined with Demecarium.	Approved
Dersalazine	The risk or severity of adverse effects can be increased when Dersalazine is combined with Mometasone.	Investigational
Dexibuprofen	The risk or severity of adverse effects can be increased when Mometasone is combined with Dexibuprofen.	Approved, Investigational
Dexketoprofen	The risk or severity of adverse effects can be increased when Mometasone is combined with Dexketoprofen.	Approved, Investigational
Dichlorvos	The risk or severity of adverse effects can be increased when Mometasone is combined with Dichlorvos.	Vet Approved
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Mometasone.	Approved, Vet Approved
Dienestrol	The serum concentration of Mometasone can be increased when it is combined with Dienestrol.	Approved, Investigational
Diethylstilbestrol	The serum concentration of Mometasone can be increased when it is combined with Diethylstilbestrol.	Approved, Investigational
Difenpiramide	The risk or severity of adverse effects can be increased when Difenpiramide is combined with Mometasone.	Experimental
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with Mometasone.	Approved, Investigational
Dipivefrin	The risk or severity of adverse effects can be increased when Mometasone is combined with Dipivefrin.	Approved
Distigmine	The risk or severity of adverse effects can be increased when Mometasone is combined with Distigmine.	Experimental
Donepezil	The risk or severity of adverse effects can be increased when Mometasone is combined with Donepezil.	Approved
Drospirenone	The risk or severity of adverse effects can be increased when Mometasone is combined with Drospirenone.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Droxicam is combined with Mometasone.	Withdrawn
Duvelisib	The risk or severity of adverse effects can be increased when Duvelisib is combined with Mometasone.	Investigational
E-6201	The risk or severity of adverse effects can be increased when E-6201 is combined with Mometasone.	Investigational
Echothiophate	The risk or severity of adverse effects can be increased when Mometasone is combined with Echothiophate.	Approved
Edrophonium	The risk or severity of adverse effects can be increased when Mometasone is combined with Edrophonium.	Approved
Enoxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Enoxacin.	Approved, Investigational
Enzalutamide	The serum concentration of Mometasone can be decreased when it is combined with Enzalutamide.	Approved
Epimestrol	The serum concentration of Mometasone can be increased when it is combined with Epimestrol.	Experimental
Epirizole	The risk or severity of adverse effects can be increased when Epirizole is combined with Mometasone.	Approved
Epitizide	Mometasone may increase the hypokalemic activities of Epitizide.	Experimental
Equol	The serum concentration of Mometasone can be increased when it is combined with Equol.	Investigational
Estradiol	The serum concentration of Mometasone can be increased when it is combined with Estradiol.	Approved, Investigational, Vet Approved
Estradiol acetate	The serum concentration of Mometasone can be increased when it is combined with Estradiol acetate.	Approved, Investigational, Vet Approved
Estradiol cypionate	The serum concentration of Mometasone can be increased when it is combined with Estradiol cypionate.	Approved, Investigational, Vet Approved
Estradiol valerate	The serum concentration of Mometasone can be increased when it is combined with Estradiol valerate.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of Mometasone can be increased when it is combined with Estriol.	Approved, Investigational, Vet Approved
Estrogens, esterified	The serum concentration of Mometasone can be increased when it is combined with Estrogens, esterified.	Approved
Estrone	The serum concentration of Mometasone can be increased when it is combined with Estrone.	Approved
Etacrynic acid	Mometasone may increase the hypokalemic activities of Etacrynic acid.	Approved, Investigational
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Mometasone.	Approved, Investigational
Ethenzamide	The risk or severity of adverse effects can be increased when Ethenzamide is combined with Mometasone.	Experimental
Ethinyl Estradiol	The serum concentration of Mometasone can be increased when it is combined with Ethinyl Estradiol.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Etodolac is combined with Mometasone.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Etofenamate is combined with Mometasone.	Approved, Investigational
Etoricoxib	The risk or severity of adverse effects can be increased when Etoricoxib is combined with Mometasone.	Approved, Investigational
Evening primrose oil	The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Mometasone.	Investigational, Nutraceutical
Exisulind	The risk or severity of adverse effects can be increased when Exisulind is combined with Mometasone.	Investigational
Felbinac	The risk or severity of adverse effects can be increased when Felbinac is combined with Mometasone.	Experimental
Fenbufen	The risk or severity of adverse effects can be increased when Fenbufen is combined with Mometasone.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Mometasone.	Approved
Fenthion	The risk or severity of adverse effects can be increased when Mometasone is combined with Fenthion.	Vet Approved
Fentiazac	The risk or severity of adverse effects can be increased when Fentiazac is combined with Mometasone.	Experimental
Feprazone	The risk or severity of adverse effects can be increased when Feprazone is combined with Mometasone.	Experimental
Ferulic acid	The risk or severity of adverse effects can be increased when Ferulic acid is combined with Mometasone.	Experimental
Fish oil	The risk or severity of adverse effects can be increased when Mometasone is combined with Fish oil.	Approved, Nutraceutical
Fleroxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Mometasone.	Approved, Withdrawn
Flumequine	The risk or severity of adverse effects can be increased when Mometasone is combined with Flumequine.	Withdrawn
Flunixin	The risk or severity of adverse effects can be increased when Flunixin is combined with Mometasone.	Vet Approved
Flunoxaprofen	The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Mometasone.	Experimental
Fluoxymesterone	Mometasone may increase the fluid retaining activities of Fluoxymesterone.	Approved, Illicit
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mometasone.	Approved, Investigational
Fosaprepitant	The serum concentration of Mometasone can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Mometasone can be decreased when it is combined with Fosphenytoin.	Approved, Investigational
Furosemide	Mometasone may increase the hypokalemic activities of Furosemide.	Approved, Vet Approved
G17DT	The risk or severity of adverse effects can be increased when Mometasone is combined with G17DT.	Investigational
Galantamine	The risk or severity of adverse effects can be increased when Mometasone is combined with Galantamine.	Approved
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when Mometasone is combined with Gallamine Triethiodide.	Approved
Garenoxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Garenoxacin.	Investigational
Gatifloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Gatifloxacin.	Approved, Investigational
Gemifloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Gemifloxacin.	Approved, Investigational
Genistein	The serum concentration of Mometasone can be increased when it is combined with Genistein.	Investigational
GI-5005	The risk or severity of adverse effects can be increased when Mometasone is combined with GI-5005.	Investigational
Ginkgo biloba	The risk or severity of adverse effects can be increased when Mometasone is combined with Ginkgo biloba.	Approved, Investigational, Nutraceutical
Ginseng	The risk or severity of adverse effects can be increased when Mometasone is combined with Ginseng.	Approved, Investigational, Nutraceutical
GLPG-0492	Mometasone may increase the fluid retaining activities of GLPG-0492.	Investigational
Glycerol Phenylbutyrate	The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Mometasone.	Approved
Grepafloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Grepafloxacin.	Approved, Investigational, Withdrawn
Guacetisal	The risk or severity of adverse effects can be increased when Guacetisal is combined with Mometasone.	Experimental
Hemoglobin crosfumaril	The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Mometasone.	Experimental
Hepatitis A Vaccine	The risk or severity of adverse effects can be increased when Mometasone is combined with Hepatitis A Vaccine.	Approved
Hepatitis B Vaccine (Recombinant)	The risk or severity of adverse effects can be increased when Mometasone is combined with Hepatitis B Vaccine (Recombinant).	Approved, Withdrawn
Hexestrol	The serum concentration of Mometasone can be increased when it is combined with Hexestrol.	Withdrawn
Higenamine	The risk or severity of adverse effects can be increased when Higenamine is combined with Mometasone.	Investigational
Human rabies virus immune globulin	The risk or severity of adverse effects can be increased when Mometasone is combined with Human rabies virus immune globulin.	Approved
Huperzine A	The risk or severity of adverse effects can be increased when Mometasone is combined with Huperzine A.	Approved, Investigational
Hyaluronidase	The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mometasone.	Approved, Investigational
Hydrochlorothiazide	Mometasone may increase the hypokalemic activities of Hydrochlorothiazide.	Approved, Vet Approved
Hydroflumethiazide	Mometasone may increase the hypokalemic activities of Hydroflumethiazide.	Approved, Investigational
Hydrotalcite	The bioavailability of Mometasone can be decreased when combined with Hydrotalcite.	Approved, Experimental, Investigational
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Mometasone.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Ibuproxam is combined with Mometasone.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with Mometasone.	Approved, Investigational
Icosapent	The risk or severity of adverse effects can be increased when Mometasone is combined with Icosapent.	Approved, Nutraceutical
Idelalisib	The serum concentration of Mometasone can be increased when it is combined with Idelalisib.	Approved
Imidazole salicylate	The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Mometasone.	Experimental
Indacaterol	Indacaterol may increase the hypokalemic activities of Mometasone.	Approved
Indapamide	Mometasone may increase the hypokalemic activities of Indapamide.	Approved
Indinavir	The serum concentration of Mometasone can be increased when it is combined with Indinavir.	Approved
Indobufen	The risk or severity of adverse effects can be increased when Indobufen is combined with Mometasone.	Investigational
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Mometasone.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Indoprofen is combined with Mometasone.	Withdrawn
INGN 201	The risk or severity of adverse effects can be increased when Mometasone is combined with INGN 201.	Investigational
INGN 225	The risk or severity of adverse effects can be increased when Mometasone is combined with INGN 225.	Investigational
Ipidacrine	The risk or severity of adverse effects can be increased when Mometasone is combined with Ipidacrine.	Experimental
Isoflurophate	The risk or severity of adverse effects can be increased when Mometasone is combined with Isoflurophate.	Approved, Investigational, Withdrawn
Isoniazid	The serum concentration of Isoniazid can be decreased when it is combined with Mometasone.	Approved, Investigational
Isoxicam	The risk or severity of adverse effects can be increased when Isoxicam is combined with Mometasone.	Withdrawn
Itraconazole	The serum concentration of Mometasone can be increased when it is combined with Itraconazole.	Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)	The risk or severity of adverse effects can be increased when Mometasone is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).	Approved
Kebuzone	The risk or severity of adverse effects can be increased when Kebuzone is combined with Mometasone.	Experimental
Ketoconazole	The serum concentration of Mometasone can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mometasone.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Mometasone.	Approved
Lacidipine	The serum concentration of Lacidipine can be decreased when it is combined with Mometasone.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Mometasone.	Approved, Investigational
Levofloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Levofloxacin.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Lisofylline is combined with Mometasone.	Investigational
Lomefloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Lomefloxacin.	Approved, Investigational
Lonazolac	The risk or severity of adverse effects can be increased when Lonazolac is combined with Mometasone.	Experimental
Lopinavir	The serum concentration of Mometasone can be increased when it is combined with Lopinavir.	Approved
Lornoxicam	The risk or severity of adverse effects can be increased when Lornoxicam is combined with Mometasone.	Approved, Investigational
Loxapine	The therapeutic efficacy of Mometasone can be decreased when used in combination with Loxapine.	Approved
Loxoprofen	The risk or severity of adverse effects can be increased when Loxoprofen is combined with Mometasone.	Approved, Investigational
Lumacaftor	The serum concentration of Mometasone can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Mometasone.	Approved, Investigational
Magaldrate	The bioavailability of Mometasone can be decreased when combined with Magaldrate.	Approved, Withdrawn
Magnesium carbonate	The bioavailability of Mometasone can be decreased when combined with Magnesium carbonate.	Approved, Investigational
Magnesium hydroxide	The bioavailability of Mometasone can be decreased when combined with Magnesium hydroxide.	Approved, Investigational
Magnesium oxide	The bioavailability of Mometasone can be decreased when combined with Magnesium oxide.	Approved
Magnesium peroxide	The bioavailability of Mometasone can be decreased when combined with Magnesium peroxide.	Experimental
Magnesium salicylate	The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Mometasone.	Approved
Magnesium silicate	The bioavailability of Mometasone can be decreased when combined with Magnesium silicate.	Approved
Magnesium Trisilicate	The bioavailability of Mometasone can be decreased when combined with Magnesium Trisilicate.	Approved
Malathion	The risk or severity of adverse effects can be increased when Mometasone is combined with Malathion.	Approved, Investigational
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Mometasone.	Approved, Investigational
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mometasone.	Approved, Vet Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mometasone.	Approved
Mefloquine	The risk or severity of adverse effects can be increased when Mometasone is combined with Mefloquine.	Approved, Investigational
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Mometasone.	Approved, Vet Approved
Memantine	The risk or severity of adverse effects can be increased when Mometasone is combined with Memantine.	Approved, Investigational
Mesalazine	The risk or severity of adverse effects can be increased when Mesalazine is combined with Mometasone.	Approved
Mesterolone	Mometasone may increase the fluid retaining activities of Mesterolone.	Experimental
Mestranol	The serum concentration of Mometasone can be increased when it is combined with Mestranol.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Mometasone.	Approved, Investigational, Withdrawn
Methallenestril	The serum concentration of Mometasone can be increased when it is combined with Methallenestril.	Experimental
Methanesulfonyl Fluoride	The risk or severity of adverse effects can be increased when Mometasone is combined with Methanesulfonyl Fluoride.	Investigational
Methyclothiazide	Mometasone may increase the hypokalemic activities of Methyclothiazide.	Approved
Methyl salicylate	The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Mometasone.	Approved, Vet Approved
Methyltestosterone	Mometasone may increase the fluid retaining activities of Methyltestosterone.	Approved
Metoclopramide	The risk or severity of adverse effects can be increased when Mometasone is combined with Metoclopramide.	Approved, Investigational
Metolazone	Mometasone may increase the hypokalemic activities of Metolazone.	Approved
Mifepristone	The therapeutic efficacy of Mometasone can be decreased when used in combination with Mifepristone.	Approved, Investigational
Minaprine	The risk or severity of adverse effects can be increased when Mometasone is combined with Minaprine.	Approved
Mitotane	The serum concentration of Mometasone can be decreased when it is combined with Mitotane.	Approved
Mivacurium	Mivacurium may increase the adverse neuromuscular activities of Mometasone.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Mizoribine is combined with Mometasone.	Investigational
Mofebutazone	The risk or severity of adverse effects can be increased when Mofebutazone is combined with Mometasone.	Experimental
Morniflumate	The risk or severity of adverse effects can be increased when Mometasone is combined with Morniflumate.	Approved
Moxestrol	The serum concentration of Mometasone can be increased when it is combined with Moxestrol.	Experimental
Moxifloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mometasone.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mometasone.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Nabumetone is combined with Mometasone.	Approved
Nafamostat	The risk or severity of adverse effects can be increased when Nafamostat is combined with Mometasone.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Mometasone.	Approved
Nalidixic Acid	The risk or severity of adverse effects can be increased when Mometasone is combined with Nalidixic Acid.	Approved, Investigational
Nandrolone	Mometasone may increase the fluid retaining activities of Nandrolone.	Experimental, Investigational
Nandrolone decanoate	Mometasone may increase the fluid retaining activities of Nandrolone decanoate.	Approved, Illicit
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Mometasone.	Approved, Vet Approved
Nefazodone	The serum concentration of Mometasone can be increased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Mometasone can be increased when it is combined with Nelfinavir.	Approved
Nemonoxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Nemonoxacin.	Investigational
Neostigmine	The risk or severity of adverse effects can be increased when Mometasone is combined with Neostigmine.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Nepafenac is combined with Mometasone.	Approved, Investigational
Nevirapine	The serum concentration of Mometasone can be decreased when it is combined with Nevirapine.	Approved
Nicorandil	The risk or severity of adverse effects can be increased when Mometasone is combined with Nicorandil.	Approved, Investigational
Nifenazone	The risk or severity of adverse effects can be increased when Nifenazone is combined with Mometasone.	Experimental
Niflumic Acid	The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Mometasone.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with Mometasone.	Approved, Investigational, Withdrawn
Nitroaspirin	The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Mometasone.	Investigational
Norfloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Norfloxacin.	Approved
Ofloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Ofloxacin.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Mometasone.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Olsalazine is combined with Mometasone.	Approved
Orgotein	The risk or severity of adverse effects can be increased when Orgotein is combined with Mometasone.	Vet Approved
Oxandrolone	Mometasone may increase the fluid retaining activities of Oxandrolone.	Approved, Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with Mometasone.	Approved
Oxolinic acid	The risk or severity of adverse effects can be increased when Mometasone is combined with Oxolinic acid.	Experimental
Oxymetholone	Mometasone may increase the fluid retaining activities of Oxymetholone.	Approved, Illicit
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mometasone.	Approved, Withdrawn
Palmidrol	The risk or severity of adverse effects can be increased when Palmidrol is combined with Mometasone.	Experimental, Nutraceutical
Paraoxon	The risk or severity of adverse effects can be increased when Mometasone is combined with Paraoxon.	Experimental
Parecoxib	The risk or severity of adverse effects can be increased when Parecoxib is combined with Mometasone.	Approved
Parthenolide	The risk or severity of adverse effects can be increased when Parthenolide is combined with Mometasone.	Approved, Investigational
Pazufloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Pazufloxacin.	Investigational
Pefloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Pefloxacin.	Approved
Pentobarbital	The serum concentration of Mometasone can be decreased when it is combined with Pentobarbital.	Approved, Investigational, Vet Approved
Phenobarbital	The serum concentration of Mometasone can be decreased when it is combined with Phenobarbital.	Approved, Investigational
Phenyl aminosalicylate	The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Mometasone.	Approved
Phenylacetic acid	The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Mometasone.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mometasone.	Approved, Vet Approved
Phenylbutyric acid	The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Mometasone.	Approved, Investigational
Phenytoin	The serum concentration of Mometasone can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Physostigmine	The risk or severity of adverse effects can be increased when Mometasone is combined with Physostigmine.	Approved, Investigational
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mometasone.	Approved, Investigational
Pipemidic acid	The risk or severity of adverse effects can be increased when Mometasone is combined with Pipemidic acid.	Experimental
Piretanide	Mometasone may increase the hypokalemic activities of Piretanide.	Approved
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Mometasone.	Approved, Investigational
Piromidic acid	The risk or severity of adverse effects can be increased when Mometasone is combined with Piromidic acid.	Experimental
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Mometasone.	Approved, Investigational
Pirprofen	The risk or severity of adverse effects can be increased when Pirprofen is combined with Mometasone.	Experimental
Polyestradiol phosphate	The serum concentration of Mometasone can be increased when it is combined with Polyestradiol phosphate.	Approved
Polythiazide	Mometasone may increase the hypokalemic activities of Polythiazide.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Mometasone is combined with Pomalidomide.	Approved
Posaconazole	The serum concentration of Mometasone can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pranoprofen	The risk or severity of adverse effects can be increased when Pranoprofen is combined with Mometasone.	Experimental, Investigational
Primidone	The serum concentration of Mometasone can be decreased when it is combined with Primidone.	Approved, Vet Approved
Proglumetacin	The risk or severity of adverse effects can be increased when Proglumetacin is combined with Mometasone.	Experimental
Promestriene	The serum concentration of Mometasone can be increased when it is combined with Promestriene.	Investigational
Propacetamol	The risk or severity of adverse effects can be increased when Propacetamol is combined with Mometasone.	Approved, Investigational
Propyphenazone	The risk or severity of adverse effects can be increased when Propyphenazone is combined with Mometasone.	Experimental
Proquazone	The risk or severity of adverse effects can be increased when Proquazone is combined with Mometasone.	Experimental
Prulifloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with Mometasone.	Investigational
Pyridostigmine	The risk or severity of adverse effects can be increased when Mometasone is combined with Pyridostigmine.	Approved, Investigational
Quinestrol	The serum concentration of Mometasone can be increased when it is combined with Quinestrol.	Approved
Quinethazone	Mometasone may increase the hypokalemic activities of Quinethazone.	Approved
Rabies virus inactivated antigen, A	The risk or severity of adverse effects can be increased when Mometasone is combined with Rabies virus inactivated antigen, A.	Approved, Investigational
Rapacuronium	Rapacuronium may increase the adverse neuromuscular activities of Mometasone.	Withdrawn
Resveratrol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Mometasone.	Approved, Experimental, Investigational
Rifabutin	The serum concentration of Mometasone can be decreased when it is combined with Rifabutin.	Approved, Investigational
Rifampicin	The serum concentration of Mometasone can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Mometasone can be decreased when it is combined with Rifapentine.	Approved, Investigational
Rindopepimut	The risk or severity of adverse effects can be increased when Mometasone is combined with Rindopepimut.	Investigational
Rivastigmine	The risk or severity of adverse effects can be increased when Mometasone is combined with Rivastigmine.	Approved, Investigational
Rofecoxib	The risk or severity of adverse effects can be increased when Rofecoxib is combined with Mometasone.	Approved, Investigational, Withdrawn
Rosoxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Rosoxacin.	Approved, Investigational
Rotavirus Vaccine	The risk or severity of adverse effects can be increased when Mometasone is combined with Rotavirus Vaccine.	Approved
Rubella virus vaccine	The risk or severity of adverse effects can be increased when Mometasone is combined with Rubella virus vaccine.	Approved, Investigational
Rufloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Rufloxacin.	Experimental
Salicylamide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Mometasone.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Mometasone.	Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigen	The risk or severity of adverse effects can be increased when Mometasone is combined with Salmonella typhi ty2 vi polysaccharide antigen.	Approved
Salmonella typhi ty21a live antigen	The risk or severity of adverse effects can be increased when Mometasone is combined with Salmonella typhi ty21a live antigen.	Approved
Salsalate	The risk or severity of adverse effects can be increased when Salsalate is combined with Mometasone.	Approved
Saquinavir	The serum concentration of Mometasone can be increased when it is combined with Saquinavir.	Approved, Investigational
Secoisolariciresinol	The serum concentration of Mometasone can be increased when it is combined with Secoisolariciresinol.	Investigational
Seliciclib	The risk or severity of adverse effects can be increased when Mometasone is combined with Seliciclib.	Investigational
Semapimod	The risk or severity of adverse effects can be increased when Semapimod is combined with Mometasone.	Investigational
Seratrodast	The risk or severity of adverse effects can be increased when Seratrodast is combined with Mometasone.	Approved
Serrapeptase	The risk or severity of adverse effects can be increased when Serrapeptase is combined with Mometasone.	Investigational
Sitafloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Sitafloxacin.	Experimental, Investigational
Sodium bicarbonate	The bioavailability of Mometasone can be decreased when combined with Sodium bicarbonate.	Approved
Sparfloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Sparfloxacin.	Approved, Investigational
SRP 299	The risk or severity of adverse effects can be increased when Mometasone is combined with SRP 299.	Investigational
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with Mometasone.	Investigational
St. John's Wort	The serum concentration of Mometasone can be decreased when it is combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stanolone	Mometasone may increase the fluid retaining activities of Stanolone.	Illicit, Investigational
Stanozolol	Mometasone may increase the fluid retaining activities of Stanozolol.	Approved, Vet Approved
Stiripentol	The serum concentration of Mometasone can be increased when it is combined with Stiripentol.	Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mometasone.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Mometasone.	Approved, Investigational
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Mometasone.	Approved, Withdrawn
Suxibuzone	The risk or severity of adverse effects can be increased when Suxibuzone is combined with Mometasone.	Experimental
Synthetic Conjugated Estrogens, A	The serum concentration of Mometasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.	Approved
Synthetic Conjugated Estrogens, B	The serum concentration of Mometasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.	Approved
Tacrine	The risk or severity of adverse effects can be increased when Mometasone is combined with Tacrine.	Investigational, Withdrawn
Talniflumate	The risk or severity of adverse effects can be increased when Mometasone is combined with Talniflumate.	Approved
Tarenflurbil	The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Mometasone.	Investigational
Tecemotide	The risk or severity of adverse effects can be increased when Mometasone is combined with Tecemotide.	Investigational
Telaprevir	The serum concentration of Telaprevir can be decreased when it is combined with Mometasone.	Approved, Withdrawn
Telithromycin	The serum concentration of Mometasone can be increased when it is combined with Telithromycin.	Approved
Temafloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Temafloxacin.	Withdrawn
Tenidap	The risk or severity of adverse effects can be increased when Tenidap is combined with Mometasone.	Experimental
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Mometasone.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Tepoxalin is combined with Mometasone.	Vet Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with Mometasone.	Approved
Testosterone	Mometasone may increase the fluid retaining activities of Testosterone.	Approved, Investigational
Testosterone cypionate	The risk or severity of edema formation can be increased when Testosterone cypionate is combined with Mometasone.	Approved
Testosterone enanthate	The risk or severity of edema formation can be increased when Testosterone enanthate is combined with Mometasone.	Approved
Testosterone propionate	Mometasone may increase the fluid retaining activities of Testosterone propionate.	Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoate	The risk or severity of fluid retention can be increased when Testosterone undecanoate is combined with Mometasone.	Approved, Investigational
TG4010	The risk or severity of adverse effects can be increased when Mometasone is combined with TG4010.	Investigational
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Mometasone.	Approved
Tibolone	The serum concentration of Mometasone can be increased when it is combined with Tibolone.	Approved, Investigational
Tinoridine	The risk or severity of adverse effects can be increased when Tinoridine is combined with Mometasone.	Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mometasone.	Approved, Investigational
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Mometasone.	Approved
Torasemide	Mometasone may increase the hypokalemic activities of Torasemide.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Tranilast is combined with Mometasone.	Approved, Investigational
Triamcinolone	The risk or severity of adverse effects can be increased when Mometasone is combined with Triamcinolone.	Approved, Vet Approved
Tribenoside	The risk or severity of adverse effects can be increased when Tribenoside is combined with Mometasone.	Experimental
Trichlorfon	The risk or severity of adverse effects can be increased when Mometasone is combined with Trichlorfon.	Vet Approved
Trichlormethiazide	Mometasone may increase the hypokalemic activities of Trichlormethiazide.	Approved, Vet Approved
Triptolide	The risk or severity of adverse effects can be increased when Triptolide is combined with Mometasone.	Investigational
Trolamine salicylate	The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Mometasone.	Approved
Tromethamine	The bioavailability of Mometasone can be decreased when combined with Tromethamine.	Approved
Trovafloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Trovafloxacin.	Approved, Investigational, Withdrawn
Tubocurarine	The risk or severity of adverse effects can be increased when Mometasone is combined with Tubocurarine.	Approved
Typhoid Vaccine	The risk or severity of adverse effects can be increased when Mometasone is combined with Typhoid Vaccine.	Approved
Tyrothricin	The risk or severity of adverse effects can be increased when Mometasone is combined with Tyrothricin.	Approved
Valdecoxib	The risk or severity of adverse effects can be increased when Valdecoxib is combined with Mometasone.	Approved, Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)	The risk or severity of adverse effects can be increased when Mometasone is combined with Varicella Zoster Vaccine (Live/Attenuated).	Approved
Voriconazole	The serum concentration of Mometasone can be increased when it is combined with Voriconazole.	Approved, Investigational
Warfarin	Mometasone may increase the anticoagulant activities of Warfarin.	Approved
Yellow Fever Vaccine	The risk or severity of adverse effects can be increased when Mometasone is combined with Yellow Fever Vaccine.	Approved, Investigational
Zaltoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mometasone.	Approved, Investigational
Zeranol	The serum concentration of Mometasone can be increased when it is combined with Zeranol.	Vet Approved
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Mometasone.	Approved, Investigational, Withdrawn
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with Mometasone.	Withdrawn

Food Interactions

Not Available

References

Synthesis Reference

Pui-Ho Yuen, Charles Eckhart, Teresa Etlinger, Nancy Levine, "Mometasone furoate monohydrate, process for making same and pharmaceutical compositions." U.S. Patent US6127353, issued April, 1988.

US6127353

General References

Not Available

External Links

Human Metabolome Database: HMDB0014902
KEGG Drug: D08227
KEGG Compound: C07816
PubChem Compound: 441335
PubChem Substance: 46505288
ChemSpider: 390090
ChEBI: 6970
ChEMBL: CHEMBL1201404
Therapeutic Targets Database: DAP001042
PharmGKB: PA450541
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
PDRhealth: PDRhealth Drug Page
Wikipedia: Mometasone

ATC Codes

R03BA07 — Mometasone

R01AD09 — Mometasone

R03AK09 — Formoterol and mometasone

D07XC03 — Mometasone

D07AC13 — Mometasone

AHFS Codes

68:04.00 — Adrenals
84:06.00 — Anti-inflammatory Agents
52:08.08 — Corticosteroids

FDA label

Download (152 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Active Not Recruiting	Treatment	Spinal Cord Injuries (SCI)	1
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Treatment	Allergic Rhinitis (AR)	2
1	Completed	Treatment	Asthma Bronchial	1
1	Completed	Treatment	Atopic Dermatitis (AD)	1
1	Completed	Treatment	Healthy Volunteers	2
1	Completed	Treatment	Psoriasis Vulgaris (Plaque Psoriasis)	1
1, 2	Completed	Not Available	Seasonal Allergic Rhinitis (SAR)	1
2	Completed	Treatment	Acute Rhinosinusitis	1
2	Completed	Treatment	Airway Inflammation / Asthma Bronchial	1
2	Completed	Treatment	Asthma Bronchial	7
2	Completed	Treatment	Chronic Rhinosinusitis	1
2	Completed	Treatment	Polyps, Nasal	1
2	Completed	Treatment	Psoriasis Vulgaris (Plaque Psoriasis)	1
2	Completed	Treatment	Rhinitis, Allergic, Perennial	1
2	Completed	Treatment	Seasonal Allergic Rhinitis (SAR)	2
2	Enrolling by Invitation	Treatment	Oesophagitis, Eosinophilic	1
2	Enrolling by Invitation	Treatment	Polyps, Nasal	1
2	Recruiting	Treatment	Sickle Cell Disorders	1
2	Suspended	Treatment	Psoriasis Vulgaris (Plaque Psoriasis)	1
2	Withdrawn	Treatment	Asthma Bronchial	1
3	Active Not Recruiting	Treatment	Asthma Bronchial	1
3	Active Not Recruiting	Treatment	Rhinitis, Allergic, Seasonal	1
3	Completed	Not Available	Perennial Allergic Rhinitis (PAR)	1
3	Completed	Supportive Care	Cancer, Breast / Dermatologic Complications / Radiation Toxicity / Skin Reactions Secondary to Radiation Therapy	1
3	Completed	Treatment	Acute Rhinosinusitis	1
3	Completed	Treatment	Allergies / Conjunctivitis / Rhinitis / Rhinoconjunctivitis	2
3	Completed	Treatment	Asthma Bronchial	6
3	Completed	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	2
3	Completed	Treatment	Chronic Rhinosinusitis / Nasal Polyposis	1
3	Completed	Treatment	Otitis Media With Effiusion	1
3	Completed	Treatment	Perennial Allergic Rhinitis (PAR)	5
3	Completed	Treatment	Perennial Allergic Rhinitis (PAR) / Rhinitis, Allergic, Perennial	1
3	Completed	Treatment	Polyps, Nasal	2
3	Completed	Treatment	Rhinitis, Allergic, Perennial	4
3	Completed	Treatment	Seasonal Allergic Rhinitis (SAR)	4
3	Not Yet Recruiting	Treatment	Allergic Rhinitis (AR)	2
3	Not Yet Recruiting	Treatment	Allergies	1
3	Recruiting	Treatment	Mild Asthma	1
3	Recruiting	Treatment	Polyps, Nasal	1
3	Unknown Status	Not Available	Itching / Nasal Obstruction / Sneezing	1
3	Unknown Status	Treatment	Mild to Moderate Persistent Allergic Rhinitis	1
3	Withdrawn	Treatment	Obstructive Sleep Apnea (Mild, Moderate, Severe) as Per Polysomnography	1
4	Active Not Recruiting	Treatment	Seasonal Allergic Rhinitis (SAR)	1
4	Completed	Not Available	Atopic Dermatitis (AD)	1
4	Completed	Other	Rhinitis, Allergic, Perennial and Seasonal	1
4	Completed	Treatment	Adenoidal Hypertrophy	1
4	Completed	Treatment	Adenoids	1
4	Completed	Treatment	Allergic Rhinitis (AR)	2
4	Completed	Treatment	Asthma Bronchial	5
4	Completed	Treatment	Asthma Bronchial / Rhinitis / Sinusitis	1
4	Completed	Treatment	Obstructive Sleep Apnea (OSA) / Perennial Allergic Rhinitis (PAR) / Sleep Disorder	1
4	Completed	Treatment	Psoriasis	1
4	Recruiting	Health Services Research	Early Radiation Dermatitis	1
4	Recruiting	Treatment	Asthma Bronchial / Sinusitis	1
4	Recruiting	Treatment	Chronic Rhinosinusitis Without Nasal Polyps	1
4	Terminated	Basic Science	Polyps, Nasal	1
4	Terminated	Treatment	Adenoidectomy / Adenoids Hypertrophy / Nasal Obstruction	1
4	Terminated	Treatment	Asthma Bronchial	2
4	Terminated	Treatment	Asthma Bronchial / Rhinitis, Allergic, Seasonal	1
4	Terminated	Treatment	Perennial Allergic Rhinitis (PAR)	1
4	Terminated	Treatment	Seasonal Allergic Rhinitis (SAR)	1
4	Unknown Status	Treatment	Asthma Bronchial / Polyps, Nasal / Sinusitis	1
4	Unknown Status	Treatment	Phimosis	1
4	Unknown Status	Treatment	Vitiligo	1
4	Withdrawn	Treatment	Enuresis / Obstructive Sleep Apnea (OSA) / Sleep Disordered Breathing (SDB)	1
Not Available	Completed	Not Available	Allergic Rhinitis (AR)	1
Not Available	Completed	Not Available	Rhinitis, Allergic, Perennial / Rhinitis, Allergic, Seasonal	1
Not Available	Completed	Not Available	Seasonal Allergic Rhinitis (SAR)	1
Not Available	Completed	Other	Asthma Bronchial	1
Not Available	Not Yet Recruiting	Not Available	Asthma in Children	1
Not Available	Recruiting	Not Available	Asthma Bronchial	1
Not Available	Suspended	Treatment	Asthma Bronchial / Rhinitis	1

Pharmacoeconomics

Manufacturers

Schering corp sub schering plough corp
Altana inc
G and w laboratories inc
Glenmark generics inc usa
Taro pharmaceuticals usa inc
Tolmar inc
Nycomed us inc
Perrigo co
Perrigo new york inc
Schering corp
Schering plough healthcare products inc
Schering-Plough

Packagers

A-S Medication Solutions LLC
Dispensing Solutions
Diversified Healthcare Services Inc.
Dixie Chem Tec Inc.
E. Fougera and Co.
G & W Labs
Glenmark Generics Ltd.
Harris Pharmaceutical Inc.
JSJ Pharmaceuticals Inc.
Lake Erie Medical and Surgical Supply
Nycomed Inc.
Perrigo Co.
Pharmedix
Physicians Total Care Inc.
Sandoz
Schering Corp.
Schering-Plough Inc.
Taro Pharmaceuticals USA
Tolmar Inc.

Dosage forms

Not Available

Prices

Unit description	Cost	Unit
Asmanex 120 Metered Doses 220 mcg/inh Aerosol 0.24 gm Inhaler	230.27USD	inhaler
Asmanex twisthaler 220 mcg #30	131.47USD	inhaler
Asmanex twisthaler 110 mcg #30	121.76USD	inhaler
Nasonex 50 mcg/act Suspension 50 mcg Nasal Spray	116.82USD	inhaler
Elocon 0.1% Lotion 60ml Bottle	86.71USD	bottle
Elocon 0.1% Cream 45 gm Tube	79.13USD	tube
Elocon 0.1% Ointment 45 gm Tube	76.45USD	tube
Mometasone Furoate 0.1% Solution 60ml Bottle	64.99USD	bottle
Mometasone Furoate 0.1% Cream 45 gm Tube	50.96USD	tube
Elocon 0.1% Lotion 30ml Bottle	49.85USD	bottle
Elocon 0.1% Ointment 15 gm Tube	49.85USD	tube
Elocon 0.1% Cream 15 gm Tube	47.68USD	tube
Mometasone Furoate 0.1% Ointment 45 gm Tube	35.99USD	tube
Mometasone Furoate 0.1% Solution 30ml Bottle	32.99USD	bottle
Mometasone Furoate 0.1% Cream 15 gm Tube	29.99USD	tube
Mometasone Furoate 0.1% Ointment 15 gm Tube	19.19USD	tube
Nasonex 50 mcg nasal spray	6.37USD	g
Elocon 0.1% cream	2.69USD	g
Mometasone furoate 0.1% cream	1.42USD	g
Elocom 0.1 % Cream	0.7USD	g
Elocom 0.1 % Ointment	0.63USD	g
Elocom 0.1 % Lotion	0.47USD	g
Pms-Mometasone 0.1 % Ointment	0.35USD	g
Ratio-Mometasone 0.1 % Ointment	0.35USD	g
Taro-Mometasone 0.1 % Ointment	0.35USD	g
Taro-Mometasone 0.1 % Lotion	0.33USD	g

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5394868	No	1995-06-25	2012-06-25
CA2282360	No	2004-11-09	2018-03-16
CA2091360	No	1997-04-08	2011-09-06
US6127353	Yes	1998-04-03	2018-04-03
US6240918	Yes	1997-08-20	2017-08-20
US8173172	Yes	1998-09-17	2018-09-17
US6503537	Yes	1998-09-17	2018-09-17
US5829434	Yes	1996-05-03	2016-05-03
US6068832	No	1997-08-27	2017-08-27
US7067502	No	2000-05-21	2020-05-21
US7566705	No	2000-05-21	2020-05-21
US8109918	No	2004-03-12	2024-03-12
US7951131	No	2004-03-12	2024-03-12
US8025635	No	2007-06-12	2027-06-12
US9585681	No	2006-04-04	2026-04-04
US7951130	No	2004-03-12	2024-03-12
US7544192	No	2006-11-29	2026-11-29
US7951133	No	2004-03-12	2024-03-12
US7713255	No	2004-03-12	2024-03-12
US7662141	No	2004-03-12	2024-03-12
US8763222	No	2012-02-08	2032-02-08

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	218-220 °C	Not Available
water solubility	Practically insoluble.	Not Available
logP	2.1	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00523 mg/mL	ALOGPS
logP	2.81	ALOGPS
logP	3.5	ChemAxon
logS	-4.9	ALOGPS
pKa (Strongest Acidic)	12.48	ChemAxon
pKa (Strongest Basic)	-3.3	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	74.6 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	110.29 m³·mol^-1	ChemAxon
Polarizability	43.82 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.995
Blood Brain Barrier	+	0.9721
Caco-2 permeable	+	0.7845
P-glycoprotein substrate	Substrate	0.7849
P-glycoprotein inhibitor I	Non-inhibitor	0.7635
P-glycoprotein inhibitor II	Non-inhibitor	0.656
Renal organic cation transporter	Non-inhibitor	0.7753
CYP450 2C9 substrate	Non-substrate	0.852
CYP450 2D6 substrate	Non-substrate	0.9135
CYP450 3A4 substrate	Substrate	0.8028
CYP450 1A2 substrate	Non-inhibitor	0.9383
CYP450 2C9 inhibitor	Non-inhibitor	0.8572
CYP450 2D6 inhibitor	Non-inhibitor	0.8429
CYP450 2C19 inhibitor	Non-inhibitor	0.8966
CYP450 3A4 inhibitor	Non-inhibitor	0.6761
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8898
Ames test	Non AMES toxic	0.8962
Carcinogenicity	Non-carcinogens	0.9393
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	1.9124 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9254
hERG inhibition (predictor II)	Non-inhibitor	0.6092

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description: This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom: Organic compounds
Super Class: Lipids and lipid-like molecules
Class: Steroids and steroid derivatives
Sub Class: Pregnane steroids
Direct Parent: Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents: 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / Halogenated steroids / 3-oxo delta-1,4-steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Alpha-chloroketones / Secondary alcohols
show 7 more
Substituents: Progestogin-skeleton / 20-oxosteroid / Hydroxysteroid / Halo-steroid / 9-halo-steroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid
show 23 more
Molecular Framework: Aliphatic homopolycyclic compounds
External Descriptors: 11beta-hydroxy steroid, 17alpha-hydroxy steroid, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, chlorinated steroid (CHEBI:6970)

Targets

Details1. Glucocorticoid receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Agonist

General Function: Zinc ion binding
Specific Function: Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name: NR3C1
Uniprot ID: P04150
Uniprot Name: Glucocorticoid receptor
Molecular Weight: 85658.57 Da

References

Isogai M, Shimizu H, Esumi Y, Terasawa T, Okada T, Sugeno K: Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol. 1993 Feb;44(2):141-5. [PubMed:8439518]
Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):S150-8. [PubMed:10518812]
Smith CL, Kreutner W: In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998 Sep;48(9):956-60. [PubMed:9793625]
Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H: Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. 2002 Aug 16;71(13):1523-34. [PubMed:12127907]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Details2. Progesterone receptor

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Agonist

General Function: Zinc ion binding
Specific Function: The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name: PGR
Uniprot ID: P06401
Uniprot Name: Progesterone receptor
Molecular Weight: 98979.96 Da

References

Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP: Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. [PubMed:15189034]

Enzymes

Details1. Cytochrome P450 2C8

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2C8
Uniprot ID: P10632
Uniprot Name: Cytochrome P450 2C8
Molecular Weight: 55824.275 Da

References

Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on July 16, 2018 21:17

Mometasone

Identification

Structure for DB00764 (Mometasone)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

References

Enzymes

References